On November 14, 2025, Merck is on the verge of reaching an agreement to acquire influenza treatment startup Cidara Therapeutics. The deal values Cidara higher than its market capitalization of US$3.3 billion, and it is expected to be announced as early as that day, with Merck emerging victorious in the competition.
